Press Releases
Debiopharm and Watson Pharmaceuticals enter into an Exclusive Licensing Agreement for two approved urology products – Trelstar® DEPOT and Trelstar®…
H3 Pharma Inc. and DSM Biologics sign development agreement for SC-1 monoclonal antibody for the treatment of gastric cancer
Mexico becomes first country to approve H3 Pharma´s Sanvar® for esophageal variecal bleeding and four other indications
Debiopharm´s Eloxatin® (Oxaliplatin) awarded Prix Galien in France for innovative cancer therapy
Debiopharm exercises its Option and signs a License Agreement with the Shanghai Institute of Materia Medica for the Development and…
Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany
Yakult Honsha files Initial Submission for Marketing Authorisation of Debiopharm´s Oxaliplatin in Japan
Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic…